A cross-sectional, cross-sectional real-world study assessing the respondents ability to return to their usual activities and the level of impairment of those activities following acute migraine treatment with lasmiditan
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms FREE
- 01 Aug 2021 New trial record
- 06 Jun 2021 Results presented at the 63rd Annual Scientific Meeting of the American Headache Society